Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22353500
DOI
10.5754/hge10330
Knihovny.cz E-resources
- MeSH
- Asymptomatic Diseases MeSH
- Biomarkers blood MeSH
- Time Factors MeSH
- Cetuximab MeSH
- Adult MeSH
- Potassium blood MeSH
- ErbB Receptors antagonists & inhibitors metabolism MeSH
- Magnesium blood MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Hypocalcemia blood chemically induced MeSH
- Hypokalemia blood chemically induced MeSH
- Protein Kinase Inhibitors adverse effects MeSH
- Kaplan-Meier Estimate MeSH
- Carcinoma drug therapy enzymology mortality secondary MeSH
- Colorectal Neoplasms drug therapy enzymology mortality pathology MeSH
- Creatinine blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Serum Albumin, Human MeSH
- Metabolic Diseases blood chemically induced mortality MeSH
- Antibodies, Monoclonal adverse effects MeSH
- Antineoplastic Agents adverse effects MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Serum Albumin metabolism MeSH
- Severity of Illness Index MeSH
- Calcium blood MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- ALB protein, human MeSH Browser
- Biomarkers MeSH
- Cetuximab MeSH
- Potassium MeSH
- EGFR protein, human MeSH Browser
- ErbB Receptors MeSH
- Magnesium MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Protein Kinase Inhibitors MeSH
- Creatinine MeSH
- Serum Albumin, Human MeSH
- Antibodies, Monoclonal MeSH
- Antineoplastic Agents MeSH
- Serum Albumin MeSH
- Calcium MeSH
BACKGROUND/AIMS: Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma. Among the side-effects of cetuximab hypomagnesaemia has been described, but the information is still limited. METHODOLOGY: We have evaluated retrospectively serum magnesium, potassium, calcium, creatinine and albumin in 51 consecutive patients with metastatic colorectal carcinoma treated with cetuximab, mostly combined with irinotecan-based combination chemotherapy. RESULTS: A significant decrease of serum magnesium, potassium, calcium and corrected serum calcium, creatinine and albumin concentrations was already evident one week after the start of treatment. Hypomagnesaemia of any grade was detected in 56% of evaluable patients, but grade 3 or grade 4 hypomagnesaemia was observed in 6% and 4% of patients, respectively. Grade 1 hypokalemia was detected in 47%, grade 3 in 17% and grade 4 hypokalemia was detected in 6% of the patients. Among evaluable patients grade 1 hypocalcaemia was detected in (36%), grade 2 hypocalcaemia in 42%, grade 3 in 4% and grade 4 in 13% of patients. Baseline hypocalcaemia of grade 1 or higher was associated with significantly inferior survival. CONCLUSIONS: Asymptomatic hypomagnesaemia, hypokalemia and hypocalcaemia are common in metastatic colorectal carcinoma patients treated with cetuximab. Hypocalcaemia is a predictor of poor prognosis.
References provided by Crossref.org
